Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Yajneon Aug 30, 2021 11:17pm
218 Views
Post# 33786381

RE:RE:RE:RE:converting data

RE:RE:RE:RE:converting dataDo you think occurred to anybody to report results consistently across the full time frame, such as the 3 patients from Ph1b...including them in all short, long and very long term results? Duh!

2b7f6fab wrote: Update to my previous comments below.  180 day column and beyond using 20% which only computes with 15 patients. (20%*12=2.4 patients doesn't work)  So the 90 day column appears to only count 12 patients and all columns beyond that 15 patients. 

Therefore adding 2 complete responses and 1 nr to the 90 day column =

6 complete response
1 partial
2 nr
6 pending

Looking at the 180 day column 20% CR is 3 patients out of 15.   Yet 2 of those should have come from Ph1b.  And we know that those 2 from Ph1b aren't respresented in columns 270 days and beyond.   Have to wait for clarification from the team in Toronto before drawing any conclusions.







2b7f6fab wrote:
For the Optimized Study Chart the 90 day column appears to consider only 12 patients since there are 8.3% used in this column which would translate to 1/.083333 =12 patients. 

There is no telling how many are used in the 180 day column, could be 12 or 15.

Jump over to 270 day column which has 6.7% is indicating 15 patients.   1/.0666667 = 15 patients.  The 360 day and the 450 day isn't showing the 2 of 3 complete response from Ph1b.

Shrugs shoulders.


 


<< Previous
Bullboard Posts
Next >>